Top

Published in:

01-07-2011 | Original Paper

Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders

Authors: Iñaki-Carril Mundiñano, Maria-Cristina Caballero, Cristina Ordóñez, Maria Hernandez, Carla DiCaudo, Irene Marcilla, Maria-Elena Erro, Maria-Teresa Tuñon, Maria-Rosario Luquin

Published in: Acta Neuropathologica | Issue 1/2011

Abstract

Olfactory dysfunction is a frequent and early feature of patients with neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) and is very uncommon in patients with frontotemporal dementia (FTD). Mechanisms underlying this clinical manifestation are poorly understood but the premature deposition of protein aggregates in the olfactory bulb (OB) of these patients might impair its synaptic organization, thus accounting for the smell deficits. Tau, β-amyloid and alpha-synuclein deposits were studied in 41 human OBs with histological diagnosis of AD (n = 24), PD (n = 6), FTD (n = 11) and compared with the OB of 15 control subjects. Tau pathology was present in the OB of all patients, irrespective of the histological diagnosis, while β-amyloid and alpha-synuclein protein deposit were frequently observed in AD and PD, respectively. Using stereological techniques we found an increased number of dopaminergic periglomerular neurons in the OB of AD, PD and FTD patients when compared with age-matched controls. Moreover, volumetric measurements of OBs showed a significant decrease only in AD patients, while the OB volume was similar to control in PD or FTD cases. The increased dopaminergic tone created in the OBs of these patients could reflect a compensatory mechanism created by the early degeneration of other neurotransmitter systems and might contribute to the olfactory dysfunction exhibited by patients with neurodegenerative disorders.

Alafuzoff I, Arzberger T, Al-Sarraj S et al (2008) Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 18:484–496PubMed

Alafuzoff I, Parkkinen L, Al-Sarraj S et al (2008) Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 67:125–143PubMedCrossRef

Alafuzoff I, Thal DR, Arzberger T et al (2009) Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:309–320PubMedCrossRef

American-Psychiatric-Association (ed) (1987) Diagnostic and statistical manual of mental disorders. Third, revised edn. Washington, DC

Arnold SE, Lee EB, Moberg PJ et al (2010) Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 67:462–469PubMedCrossRef

Attems J, Jellinger KA (2006) Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 25:265–271PubMed

Beach TG, White CL, Hamilton RL et al (2008) Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 116:277–288PubMedCrossRef

Beach TG, White CL 3rd, Hladik CL et al (2009) Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117:169–174PubMedCrossRef

Belzunegui S, Sebastián WS, Garrido-Gil P et al (2007) The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 61:1006–1012PubMedCrossRef

10.

Berkowicz DA, Trombley PQ (2000) Dopaminergic modulation at the olfactory nerve synapse. Brain Res 855:90–99PubMedCrossRef

11.

Bhatnagar KP, Kennedy RC, Baron G, Greenberg RA (1987) Number of mitral cells and the bulb volume in the aging human olfactory bulb: a quantitative morphological study. Anat Rec 218:73–87PubMedCrossRef

12.

Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY (2008) Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 447:12–16PubMedCrossRef

13.

Bohnen NI, Muller ML, Kotagal V et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754PubMedCrossRef

14.

Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRef

15.

Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

16.

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404PubMedCrossRef

17.

Cairns NJ, Bigio EH, Mackenzie IR et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22PubMedCrossRef

18.

Cavalieri B (1966) Geometria degli indivisibile. Unione Tipografico-Editrice. Torino

19.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30:7281–7289PubMedCrossRef

20.

Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G (1995) Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 89:291–295PubMedCrossRef

21.

Christen-Zaech S, Kraftsik R, Pillevuit O et al (2003) Early olfactory involvement in Alzheimer’s disease. Can J Neurol Sci 30:20–25PubMed

22.

Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H (2008) Olfaction in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 29:693–706PubMedCrossRef

23.

Doty RL, Reyes PF, Gregor T (1987) Presence of both odor identification and detection deficits in Alzheimer’s disease. Brain Res Bull 18:597–600PubMedCrossRef

24.

Duda JE (2010) Olfactory system pathology as a model of Lewy neurodegenerative disease. J Neurol Sci 289:49–54PubMedCrossRef

25.

Ennis M, Zimmer LA, Shipley MT (1996) Olfactory nerve stimulation activates rat mitral cells via NMDA and non-NMDA receptors in vitro. Neuroreport 7:989–992PubMedCrossRef

26.

Esiri MM, Wilcock GK (1984) The olfactory bulbs in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 47:56–60PubMedCrossRef

27.

Fusetti M, Fioretti AB, Silvagni F et al (2010) Smell and preclinical Alzheimer disease: study of 29 patients with amnesic mild cognitive impairment. J Otolaryngol Head Neck Surg 39:175–181PubMed

28.

German DC, Manaye KF, White CL 3rd et al (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667–676PubMedCrossRef

29.

Ghatpande AS, Gelperin A (2009) Presynaptic muscarinic receptors enhance glutamate release at the mitral/tufted to granule cell dendrodendritic synapse in the rat main olfactory bulb. J Neurophysiol 101:2052–2061PubMedCrossRef

30.

Gomez-Isla T, Hollister R, West H et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41:17–24PubMedCrossRef

31.

Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 28:327–335PubMedCrossRef

32.

Gundersen HJ, Bendtsen TF, Korbo L et al (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379–394PubMedCrossRef

33.

Haehner A, Boesveldt S, Berendse HW et al (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15:490–494PubMedCrossRef

34.

Hawkes C (2003) Olfaction in neurodegenerative disorder. Mov Disord 18:364–372PubMedCrossRef

35.

Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:436–446PubMedCrossRef

36.

Hirano S, Shinotoh H, Shimada H et al (2010) Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 133:2058–2068PubMedCrossRef

37.

Hoogland PV, Huisman E (1999) Tyrosine hydroxylase immunoreactive structures in the aged human olfactory bulb and olfactory peduncle. J Chem Neuroanat 17:153PubMedCrossRef

38.

Hoogland PV, van den Berg R, Huisman E (2003) Misrouted olfactory fibres and ectopic olfactory glomeruli in normal humans and in Parkinson and Alzheimer patients. Neuropathol Appl Neurobiol 29:303–311PubMedCrossRef

39.

Hsia AY, Vincent JD, Lledo PM (1999) Dopamine depresses synaptic inputs into the olfactory bulb. J Neurophysiol 82:1082–1085PubMed

40.

Huey ED, Putnam KT, Grafman J (2006) A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66:17–22PubMedCrossRef

41.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef

42.

Huisman E, Uylings HBM, Hoogland PV (2004) A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord 19:687–692PubMedCrossRef

43.

Huisman E, Uylings HB, Hoogland PV (2008) Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson’s disease patients. Mov Disord 23:1407–1413PubMedCrossRef

44.

Hummel T, Witt M, Reichmann H, Welge-Luessen A, Haehner A (2010) Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson’s disease. J Neurol Sci 289:119–122PubMedCrossRef

45.

Ibarretxe-Bilbao N, Junque C, Marti MJ et al (2010) Olfactory impairment in Parkinson’s disease and white matter abnormalities in central olfactory areas: a voxel-based diffusion tensor imaging study. Mov Disord 25:1888–1894PubMedCrossRef

46.

Jellinger KA (2009) Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117:215–216 (author reply 217–218)PubMedCrossRef

47.

Kása P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer’s disease. Prog Neurobiol 52:511–535PubMedCrossRef

48.

Kovács CL (1999) B-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer’s disease. Neuropathol Appl Neurobiol 25:481–491PubMedCrossRef

49.

Kovacs I, Torok I, Zombori J, Kasa P (1998) Cholinergic structures and neuropathologic alterations in the olfactory bulb of Alzheimer’s disease brain samples. Brain Res 789:167–170PubMedCrossRef

50.

Kovács T (2004) Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Res Rev 3:215PubMedCrossRef

51.

Kril JJ, Patel S, Harding AJ, Halliday GM (2002) Neuron loss from the hippocampus of Alzheimer’s disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol 103:370–376PubMedCrossRef

52.

Lehericy S, Hirsch EC, Cervera-Pierot P et al (1993) Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease. J Comp Neurol 330:15–31PubMedCrossRef

53.

Luzzi S, Snowden JS, Neary D, Coccia M, Provinciali L, Lambon Ralph MA (2007) Distinct patterns of olfactory impairment in Alzheimer’s disease, semantic dementia, frontotemporal dementia, and corticobasal degeneration. Neuropsychologia 45:1823–1831PubMedCrossRef

54.

BJ Maher, Westbrook GL (2008) Co-transmission of dopamine and GABA in periglomerular cells. J Neurophysiol 99:1559–1564CrossRef

55.

McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef

56.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed

57.

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 58:1803–1809PubMedCrossRef

58.

Mesholam RI, Moberg PJ, Mahr RN, Doty RL (1998) Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol 55:84–90PubMedCrossRef

59.

Mossner R, Schmitt A, Syagailo Y, Gerlach M, Riederer P, Lesch KP (2000) The serotonin transporter in Alzheimer’s and Parkinson’s disease. J Neural Transm Suppl (60):345–350

60.

Mueller A, Abolmaali ND, Hakimi AR et al (2005) Olfactory bulb volumes in patients with idiopathic Parkinson’s disease a pilot study. J Neural Transm 112:1363PubMedCrossRef

61.

Nai Q, Dong HW, Hayar A, Linster C, Ennis M (2009) Noradrenergic regulation of GABAergic inhibition of main olfactory bulb mitral cells varies as a function of concentration and receptor subtype. J Neurophysiol 101:2472–2484PubMedCrossRef

62.

Nai Q, Dong HW, Linster C, Ennis M (2010) Activation of alpha1 and alpha2 noradrenergic receptors exert opposing effects on excitability of main olfactory bulb granule cells. Neuroscience 169:882–892PubMedCrossRef

63.

Ohm TG, Braak H (1987) Olfactory bulb changes in Alzheimer’s disease. Acta Neuropathol 73:365–369PubMedCrossRef

64.

Pardini M, Huey ED, Cavanagh AL, Grafman J (2009) Olfactory function in corticobasal syndrome and frontotemporal dementia. Arch Neurol 66:92–96PubMedCrossRef

65.

Parkkinen L, Silveira-Moriyama L, Holton JL, Lees AJ, Revesz T (2009) Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders”. Acta Neuropathol 117:213–214 (author reply 217–218)PubMedCrossRef

66.

Pearce RKB, Hawkes CH, Daniel SE (1995) The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10:283–287PubMedCrossRef

67.

Petzold GC, Hagiwara A, Murthy VN (2009) Serotonergic modulation of odor input to the mammalian olfactory bulb. Nat Neurosci 12:784–791PubMedCrossRef

68.

Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW (2000) New dopaminergic neurons in Parkinson’s disease striatum. Lancet 356:44–45PubMedCrossRef

69.

Pressler RT, Inoue T, Strowbridge BW (2007) Muscarinic receptor activation modulates granule cell excitability and potentiates inhibition onto mitral cells in the rat olfactory bulb. J Neurosci 27:10969–10981PubMedCrossRef

70.

Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 12:295–312PubMedCrossRef

71.

Ridha B, Anderson V, Barnes J et al (2008) Volumetric MRI and cognitive measures in Alzheimer disease. J Neurol 255:567PubMedCrossRef

72.

Rombaux P, Potier H, Markessis E, Duprez T, Hummel T (2010) Olfactory bulb volume and depth of olfactory sulcus in patients with idiopathic olfactory loss. Eur Arch Otorhinolaryngol 267(10):1551–1556PubMedCrossRef

73.

Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson’s disease. Biochem Pharmacol 74:177–190PubMedCrossRef

74.

Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63:167–173PubMedCrossRef

75.

Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y (1986) Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease. Brain Res 362:83–91PubMedCrossRef

76.

San Sebastian W, Guillen J, Manrique M et al (2007) Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft. Brain 130:1306–1316PubMedCrossRef

77.

Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30:8083–8095PubMedCrossRef

78.

Sengoku R, Saito Y, Ikemura M et al (2008) Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67:1072–1083PubMedCrossRef

79.

Serby M, Larson P, Kalkstein D (1991) The nature and course of olfactory deficits in Alzheimer’s disease. Am J Psychiatry 148:357–360PubMed

80.

Shimada H, Hirano S, Shinotoh H et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278PubMedCrossRef

81.

Smith RL, Baker H, Kolstad K, Spencer DD, Greer CA (1991) Localization of tyrosine hydroxylase and olfactory marker protein immunoreactivities in the human and macaque olfactory bulb. Brain Res 548:140–148PubMedCrossRef

82.

Smutzer GS Arnold SE, Doty RL, Trojanowski JQ (2003) Olfactory system neuropathology in neurodegenerative diseases and schizophrenia. In: Doty RL (ed) Handbook of olfaction and gustation, 2nd edn. Marcel Dekker, New York

83.

Stephenson R, Houghton D, Sundarararjan S et al (2010) Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson’s disease. Mov Disord 25:2099–2104PubMedCrossRef

84.

Talamo BR, Feng WH, Perez-Cruet M et al (1991) Pathologic changes in olfactory neurons in Alzheimer’s disease. Ann NY Acad Sci 640:1–7PubMed

85.

Tande D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, Francois C (2006) New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129:1194–1200PubMedCrossRef

86.

Thomann PA, Dos Santos V, Seidl U, Toro P, Essig M, Schröder J (2009) MRI-derived atrophy of the olfactory bulb and tract in mild cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis 17:213–221

87.

Thomann PA, Dos Santos V, Toro P, Schönknecht P, Essig M, Schröder J (2009) Reduced olfactory bulb and tract volume in early Alzheimer’s disease—a MRI study. Neurobiol Aging 30:838–841PubMedCrossRef

88.

Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW (2003) Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol 29:503–510PubMedCrossRef

89.

Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, Argandona-Palacios L, Garcia-Munozguren S, Martinez-Marcos A (2010) Alpha-synucleinopathy in the human olfactory system in Parkinson’s disease: involvement of calcium-binding protein- and substance P-positive cells. Acta Neuropathol 119:723–735PubMedCrossRef

90.

Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedCrossRef

91.

Vyhnalek M, Lodinska D, Varjassyova A, Horinek D, Laczo J, Hort J (2006) Olfactory function impairment in frontotemporal dementia is evident but less severe than in Alzheimer’s disease (Abstract). Eur J Neurol 13:71

92.

Wattendorf E, Welge-Lussen A, Fiedler K et al (2009) Olfactory impairment predicts brain atrophy in Parkinson’s disease. J Neurosci 29:15410–15413PubMedCrossRef

93.

Weinshenker D (2008) Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 5:342–345PubMedCrossRef

94.

Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA (2009) Olfactory impairment in presymptomatic Alzheimer’s disease. Ann NY Acad Sci 1170:730–735PubMedCrossRef

95.

Witt M, Bormann K, Gudziol V et al (2009) Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov Disord 24:906–914PubMedCrossRef

96.

Yan Z, Feng J (2004) Alzheimer’s disease: interactions between cholinergic functions and beta-amyloid. Curr Alzheimer Res 1:241–248PubMedCrossRef

97.

Yang Y, Schmitt HP (2001) Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol 101:256–270PubMed

98.

Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341PubMedCrossRef

Title: Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders
Authors: Iñaki-Carril Mundiñano
Maria-Cristina Caballero
Cristina Ordóñez
Maria Hernandez
Carla DiCaudo
Irene Marcilla
Maria-Elena Erro
Maria-Teresa Tuñon
Maria-Rosario Luquin
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 1/2011
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-011-0830-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death

A harmonized classification system for FTLD-TDP pathology

Pathogenic T cell responses against aquaporin 4

The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene

Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease